^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ART4215

    i
    Other names: ART4215, ART 4215, ART-4215
    Associations

    News

    Trials
    Company:
    Artios Pharma
    Drug class:
    POLQ inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=390, Active, not recruiting, Artios Pharma Ltd | Phase classification: P1/2 --> P1 | Trial completion date: Jan 2026 --> Aug 2025 | Trial primary completion date: Aug 2025 --> Mar 2025
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    Talzenna (talazoparib) • Zejula (niraparib) • ART4215
    11ms
    A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=390, Active, not recruiting, Artios Pharma Ltd | Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Jan 2026 | Trial primary completion date: Mar 2025 --> Aug 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative
    |
    Talzenna (talazoparib) • Zejula (niraparib) • ART4215
    almost2years
    A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=290, Recruiting, Artios Pharma Ltd | N=206 --> 290
    Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative
    |
    Talzenna (talazoparib) • Zejula (niraparib) • ART4215
    3years
    A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=206, Recruiting, Artios Pharma Ltd | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative
    |
    Talzenna (talazoparib) • ART4215
    over3years
    A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=206, Not yet recruiting, Artios Pharma Ltd
    Clinical • New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative
    |
    Talzenna (talazoparib) • ART4215